Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Jun‐Zhe Yi
Observed names:
JUNZHE YI,
Jun-Zhe Yi,
Junzhe Yi
Institutions:
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
Observed institutions:
Sun Yat-sen University,
Sun Yat-sen University Cancer Center,
State Key Laboratory of Oncology in South China
ORCID:
0000-0002-0588-2060
Observed ORCID:
0000-0002-0588-2060
OpenAlex ID:
A5101490076
Mesenchymal stromal cells alleviate depressive and anxiety-like behaviors via a lung vagal-to-brain axis in male mice
2023
·
Jing Huang
, Weijun Huang
, et al.
·
Nature Communications
·
81
PDF
Arterial chemotherapy for hepatocellular carcinoma in China: consensus recommendations
2023
·
Ming Zhao
, Zhi Guo
, et al.
·
Hepatology International
·
73
Waist circumference increases risk of coronary heart disease: Evidence from a Mendelian randomization study
2020
·
Qinchang Chen
, Lingling Li
, et al.
·
Molecular Genetics & Genomic Medicine
·
46
PDF
CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression
2024
·
JUNZHE YI
, BINBIN LI
, et al.
·
Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
·
37
PDF
Immunotherapy in older patients with hepatocellular carcinoma
2021
·
Ning Lyu
, Jun-Zhe Yi
, et al.
·
European Journal of Cancer
·
31
Recommended 10-Year Follow-Up Strategy for Small Hepatocellular Carcinoma After Radiofrequency Ablation: A Cost-Effectiveness Evaluation
2024
·
Qi-Feng Chen
, Song Chen
, et al.
·
The American Journal of Gastroenterology
·
16
Combining immune checkpoint inhibitors and molecular-targeted agents with hepatic arterial infusion chemotherapy for hepatocellular carcinoma with inferior vena cava and/or right atrium tumor thrombus
2025
·
Suixing Zhong
, Junzhe Yi
, et al.
·
Hepatology International
·
10
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real‐world study
2023
·
Jun‐Zhe Yi
, Zhi‐Jian Zhu
, et al.
·
Hepatology Research
·
7
Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis
2025
·
Jun-Zhe Yi
, Jie Xu
, et al.
·
Frontiers in Immunology
·
6
PDF
Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma
2025
·
Yi-Min Zhang
, Xin-Tong Wu
, et al.
·
Liver Cancer
·
5
Additional Hepatic Arterial Infusion Chemotherapy to Sorafenib Was Cost-Effective for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis
2024
·
Qi-Feng Chen
, Xiong-Ying Jiang
, et al.
·
Journal of Hepatocellular Carcinoma
·
3
PDF
Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as a first-line treatment for unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis
2025
·
Yue Hu
, Xiong-Ying Jiang
, et al.
·
Journal of Gastrointestinal Oncology
·
2
Durvalumab plus HAIC-FOLFOX followed by maintenance durvalumab for hepatocellular carcinoma with major portal invasion: phase 2 DurHope study
2026
·
Junzhe Yi
, Jiongliang Wang
, et al.
·
Nature Communications
First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses.
2025
·
Ming Zhao
, Ning Lyu
, et al.
·
Journal of Clinical Oncology
First-line durvalumab with arterial chemotherapy in major portal invaded hepatocellular carcinoma: The phase 2 DurHope study with biomolecular analyses.
2025
·
Ming Zhao
, Ning Lyu
, et al.
·
Journal of Clinical Oncology
Dysfunction in neuro-mesenchymal units impairs the development of bone marrow B cells in mice with anxiety
2024
·
Heshe Li
, Junzhe Yi
, et al.
·
Brain Behavior and Immunity
Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma–Authors' reply
2024
·
Jun‐Zhe Yi
, Ning Lyu
, et al.
·
Hepatology Research
Show more works
View as search
Works count:
17
Citation count:
317
H-index:
7
I10-index:
7
Year
Topic
Type